SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published inStrokeentitled "Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke." Co-authors include Michael L. Levy, MD, PhD, John R. Crawford, MD, Nabil Dib, MD, Lev Verkh, PhD, Nikolai Tankovich, MD, PhD and Steven C. Cramer, MD.
As indicated in theStrokepublication, "Stroke is perennially among the leading causes of human disability and the leading neurological cause of lost disability-adjusted life years. The mean survival after stroke is 6-7 years, with more than 85% of patients living past the first-year post-stroke, many with years of enduring disability. Many restorative therapies are under study to improve outcomes after stroke." However, restorative therapies often have a short time window for improvement usually measured in days-months.
"Based on Stemedica's preclinical data that supported the safety and efficacy of its MSCs as a restorative therapy to improve outcomes after stroke, the company was granted approval by the FDA to conduct a Phase I/IIa dose escalation trial that examined the effects of a single IV infusion of Stemedica's cGMP manufactured allogeneic ischemia-tolerant MSCs," said Dr. Lev Verkh, Chief Regulatory and Clinical Development Officer of Stemedica.
Study:The target population included patients with chronic ischemic stroke and substantial functional deficits; a group for whom treatment options remained limited. The primary outcome of the study was safety, based on serial measures of behavior, CT scans, and laboratory testing. Four secondary endpoints were scored serially to derive estimates of behavioral changes relatively to the baseline over a period of 12 months: NIH Stroke Scale (NIHSS) for neurological assessment, Barthel Index (BI) for ability to perform daily tasks, Mini-Mental Status Exam (MMSE) for mental status, and Geriatric Depression Scale (GDS) for degree of depression. The study was conducted at three centers: University of California, San Diego (UCSD); Mercy Gilbert Medical Center, Gilbert, Arizona; and University of California, Irvine (UCI).
Entry criteria included ischemic stroke >6 months prior to administration, substantial functional deficits (subject confined to a wheelchair, had home-nursingcare, orneeded assistance withactivities ofdailyliving), no substantial improvement in neurologic orfunctional deficits for the2 months prior to enrollment in thestudypermedical history, and NIHSS score=6-20.
Enrollees received a single intravenous dose of allogeneic mesenchymal bone marrow cells. Phase I used a dose escalation design (3 tiers, n=5 each). Phase IIa (n=21) was an expanded safety cohort. The primary endpoint was safety over 1-year. Secondary endpoints examined behavior, with a pre-specified focus at 6-months.
Subject status at enrollment prior to treatment:At baseline, subjects (n=36) averaged 4.24.6 years post-stroke, age 61.110.8 years, NIHSS score 8 [6.5-10], and Barthel Index 6529.
Safety:Study testing disclosed no safety concerns. No subject showed a positive reaction to intradermal testing. In Phase I, each dose (0.5, 1.0, and 1.5 million cells/kg body weight) was found safe, as a result Phase IIa subjects received 1.5 million cells/kg. Two subjects were lost to follow-up, one was withdrawn, and two died (unrelated to study treatment). There were 15 serious adverse events, none possibly or probably related to study treatment. Two mild adverse events were possibly related to study treatment, a urinary tract infection and IV site irritation. Treatment was determined to be safe based on serial exams, EKGs, laboratory tests, and pan-CT scans.
Behavioral Effects:Improvements across all subjects post-transfusion and for all four secondary endpoints were achieved. Improvements in each index were: Barthel Index (6.811.4 points, p=0.002); in NIHSS (-1.251.7 points, p<0.001); Mini Mental Status Exam (1.82.8 points, p<0.001); and Geriatric Depression Scale (-1.63.8 points, p=0.015). At baseline 11.4% (4/35 subjects) had Barthel Index=95-100 (favorable outcome); at 6-months, 27.3% (9/33); by 12-months, 35.5% (11/31).
Conclusions:The current study is the largest trial of intravenous MSCs in patients with chronic stroke and the first to evaluate allogeneic MSC therapy in this population. It is also the first study to evaluate MSCs grown under hypoxic conditions favorable to cell proliferation, gene expression, cytokine production and migration. While patients with stroke in the chronic stage generally show significant functional decline, enrollees in the current study showed 12 months of continued functional improvements across all secondary endpoints.
Intravenous transfusion of allogeneic ischemia tolerant MSCs in patients with chronic stroke and substantial functional deficits was safe and suggested behavioral gains. These data support proceeding to a randomized, placebo-controlled study of this therapy in this population.
Dr. Nikolai Tankovich, President and Chief Medical Officer added, "Stemedica is encouraged by the results of the study which demonstrated safety and preliminary efficacy of its cell therapy product for the treatment of chronic ischemic stroke patients. It is a significant milestone for Stemedica to bring this new cellular medication to patients with debilitating conditions caused by a stroke. Stemedica plans to move forward to a Phase-IIb discussion with the FDA."
Michael Levy, MD, PhD, FACS, FAANS, Professor of Neurosurgery at UCSD and the Principal Investigator of this study commented: "Based on my clinical trial work in Stemedica's Ischemic Stroke trial, my experience to date with Stemedica's allogeneic ischemic tolerant mesenchymal stem cell product suggests that the product is first and foremost safe and secondarilyhas the potential to produce unparalleled medical benefits."
About Stemedica Cell Technologies, Inc.Stemedica Cell Technologies, Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for ischemic stroke, and Alzheimer's Disease. Stemedica's cell are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California and can be found online atwww.stemedica.com.
Forward Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Media ContactStemedica Cell Technologies, Inc.Dave McGuiganEVP, Marketing & Business Developmentdmcguigan@stemedica.com+1 858-658-0910 x7203
SOURCE Stemedica Cell Technologies, Inc.
- Naturally Treat & Heal The Cause of Pain with Regenerative Therapies - The Mountaineer - May 15th, 2021
- CAR T-Cell Therapy UCARTCS1A Shows Early Activity in Relapsed/Refractory Myeloma - OncLive - May 15th, 2021
- Rinri Therapeutics Secures Innovate UK Funding Grant for 3.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing Loss - PRNewswire - May 15th, 2021
- With $52 Million Series A, Appia Bio Anticipates a Bright Future in Cell Therapy - BioSpace - May 15th, 2021
- Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon Delivered Tumor-Focused Interferon ExpressionData presented at the 2021 American Society... - May 15th, 2021
- Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation - DocWire News - May 15th, 2021
- Fascination with stem cell sensation leads to Fulbright scholarship - Monash University - May 15th, 2021
- Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress - Business Wire - May 15th, 2021
- Munshi Explains Staging, Prognosis, and Treatment for a Patient With Acute Graft-vs-Host-Disease - Targeted Oncology - May 15th, 2021
- KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma - DocWire News - May 15th, 2021
- Icy Microneedle Patch Delivers Cell Therapy, Then Melts - Freethink - May 15th, 2021
- FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz IND for Stroke Treatment - BioSpace - May 15th, 2021
- Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2021 Type and End-use Industry 2026 Orange County Hair Restoration Center,... - May 15th, 2021
- Allogeneic Mesenchymal Stem Cell Segment Is Expected To Lead In the Global Rheumatoid Arthritis Stem Cell Therapy Market over the Forecast Period,... - May 15th, 2021
- Advanced Therapy Medicinal Products Market Size Worth $21.2 Billion By 2028: Grand View Research, Inc. - PRNewswire - May 15th, 2021
- New connection between metabolism and red blood cell development - Harvard Gazette - May 15th, 2021
- Heart attack recovery aided by injecting heart muscle cells that overexpress cyclin D2 - The Mix - May 15th, 2021
- Vertex and CRISPR Therapeutics to Present New Clinical Data - GlobeNewswire - May 15th, 2021
- Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs... - May 15th, 2021
- Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 - Yahoo Finance - May 3rd, 2021
- Stem cell therapy for COPD: Cost, effectiveness, and more - Medical News Today - May 3rd, 2021
- Thomas Smeenk on Hemostemix's autologous stem cell therapy technology and why some call it 'the fountain of youth' - InvestorIntel - May 3rd, 2021
- Mesoblast says its stem cell treatment saved lives of severely ill COVID patients - Stockhead - May 3rd, 2021
- Antiviral T cells protected, viable as off-the-shelf treatment for painful complication stem cells - Microbioz India - May 3rd, 2021
- Investigating CAR T-Cell Therapy for Use in Different Disease Types - Targeted Oncology - May 3rd, 2021
- Should scientists be allowed to grow human embryos in a dish beyond 14 days? Is it scientifically important or morally wrong? - USA TODAY - May 3rd, 2021
- Hope, hype and exploitation the wild history of stem cell science - ABC News - May 3rd, 2021
- Brave New World is being reinvented with synthetic embryosand the right reasons - SYFY WIRE - May 3rd, 2021
- Stem Cell Therapy Market Trends Evaluation 2021 By Leading Players Updates, Consumer-Demand, Key Strategies, Consumption, Industry Development, Market... - May 3rd, 2021
- STEM NOLA Teams with Obatala Science & CellSpring to Expose Students to Careers and Medical Research at Biotech Startups - PRNewswire - May 3rd, 2021
- Breakthrough gene therapies in sight | UNC-Chapel Hill - UNC Chapell Hill - May 3rd, 2021
- FDA's Abecma Approval a 'Great Blessing' for Patients with Multiple Myeloma - Curetoday.com - May 3rd, 2021
- Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in... - May 3rd, 2021
- Global Stem Cell Therapy Market 2020-2027 Trends, industry vertical, along with the geography, delivering valuable insights | Reportspedia Clark... - May 3rd, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market Report 2021 by Global Key Players, Types, Applications, Countries, Size, Forecast to 2027 Clark County... - May 3rd, 2021
- CRISPRoff Reversible Epigenome Editing Method Could Enable Safer, More Precise Therapeutics - GenomeWeb - May 3rd, 2021
- Cell Therapy Market To Expand At An expeditious Growth Rate From 2021-2027 | Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix,... - May 3rd, 2021
- FTC continues to crack down on companies peddling fake COVID treatments and cures - HamletHub - May 3rd, 2021
- ThermoGenesis : The History of Cell and Gene Therapy - marketscreener.com - April 18th, 2021
- Russell Health Honored in Global Business Leaders Magazine's '20 Leading Companies of the Year 2021' - PRNewswire - April 18th, 2021
- Durable B-ALL Control With Allogeneic Transplant After CAR T-Cell Therapy - Cancer Therapy Advisor - April 18th, 2021
- CRISPR lauds easy scale-out of cell therapy - BioProcess Insider - BioProcess Insider - April 18th, 2021
- NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs)... - April 18th, 2021
- CRISPR gene therapy for sickle cell disease approved by the FDA - BioNews - April 18th, 2021
- Man's heart healed by stem cell therapy and love of an old flame - Leeds Live - April 18th, 2021
- Autologous Stem Cell Based Therapies Market Professional Report 2021 Witness Robust Expansion by 2026 SoccerNurds - SoccerNurds - April 18th, 2021
- Stem Cell Therapy Market Analysis 2021: Size, Share, Sales, Growth, Revenue, Type, Application & Forecast To 2027 SoccerNurds - SoccerNurds - April 18th, 2021
- Mastitis therapy explored | AG | kmaland.com - KMAland - April 18th, 2021
- CAR T-Cell Therapy Enters the Arena in Multiple Myeloma With Ongoing Research Ahead - OncLive - April 18th, 2021
- Leukemia Cutis: Symptoms and Treatment - Healthline - April 18th, 2021
- Stem Cell Therapy Market is Set to Witness Impressive Growth | Top Players Osiris Therapeutics, Inc. (US), MEDIPOST Co., Ltd. KSU | The Sentinel... - April 18th, 2021
- Global Stem Cell Therapy Market 2020 SWOT Analysis, Growth Rate, and Market Share By Type, Application and Global Forecast 2027 - Los Hijos de la... - April 18th, 2021
- Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2025 - The Courier - March 8th, 2021
- Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 - The Courier - March 8th, 2021
- Pericardial Injection Effective, Less Invasive Way to Get Regenerative Therapies to Heart - NC State News - March 8th, 2021
- Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging - OncLive - March 8th, 2021
- Glial Cell Discovery Could Point the Way to Motor Neuron Disease Therapies - Technology Networks - March 8th, 2021
- Mouth Sores from Chemo: Symptoms, Causes, and Treatments - Healthline - February 19th, 2021
- ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry - PRNewswire - February 19th, 2021
- Meet the women hoping to recruit more stem cells donors from Black communities - CTV News - February 19th, 2021
- CAR T-Cell Therapy Carves Out a Role in Multiple Myeloma - OncLive - February 19th, 2021
- AI project to power the future of stem cell manufacturing - TechCentral.ie - February 17th, 2021
- Promising Results for Stem Cell Treatment of Degenerative ... - February 14th, 2021
- Stem Cell Therapy for Heart Disease - Cleveland Clinic - February 14th, 2021
- Stem Cell Therapy for Stroke Recovery | University of ... - February 14th, 2021
- Stem Cell Treatment: Future of Modern Medicine | Science Times - February 14th, 2021
- Researchers may have found a miracle cure for baldness - BGR - February 14th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease -... - February 14th, 2021
- Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier - February 14th, 2021
- Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment - Curetoday.com - February 14th, 2021
- Network-based screen in iPSC-derived cells reveals therapeutic candidate for heart valve disease - Science - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Orchard Therapeutics talks the benefits of HSC therapy - BioProcess Insider - February 14th, 2021
- Protein Discovery in the Development of New Hearing Hair Cells Could Lead to Treatments for Hearing Loss - SciTechDaily - February 7th, 2021
- Stem cells efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review - February 4th, 2021
- Groundbreaking Trial Shows Umbilical-Cord Derived Mesenchymal Stem Cell Infusions Save Lives of Sickest COVID-19 Patients - HospiMedica - January 22nd, 2021
- Massive Growth in Canine Stem Cell Therapy Market Set to Witness Huge Growth by 2027| VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana... - January 22nd, 2021
- Autologous stem cell transplantation versus bortezomib for the first line treatment of systemic light chain amyloidosis in the UK - DocWire News - January 22nd, 2021
- Promising Steps Toward Retinal Cell Transplants to Fight Blindness - HealthDay News - January 22nd, 2021